START will leverage Trialing’s platform to distribute curated information on ongoing early-phase oncology trials.

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research ...

Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study ...

The demand for clarity from National Institutes of Health Director Dr. Jayanta “Jay” Bhattacharya comes on the heels of a ...

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals ...

BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

LAKE ZURICH, IL, UNITED STATES, March 17, 2026 /EINPresswire.com/ -- The Sikh community in the United States, estimated ...

The British Pharmacological Society has called for clearer, evidence-based guidance on medication use during pregnancy and ...

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ...

What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...